Quest PharmaTech Inc.
Loading stock data...
Stock Performance
Price History
-
Drag to select time range
-
Market Data
Market Cap
5.1M
P/E Ratio
-
52-Week High
-
52-Week Low
-
Avg Volume
-
Beta
-
Forward P/E
-
Dividend Yield
-
EV/Revenue
-
Price/Book
-
Business Overview
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Healthcare
Biotechnology
TSXV
Key Financial Metrics
-
Revenue
-1.8M
Net Income
C$-0.01
EPS (Diluted)
-511,878
Free Cash Flow
Profitability
Gross Margin
-
Operating Margin
-
Net Profit Margin
-
EBITDA
-1.8M
Returns & Efficiency
Return on Assets (ROA)
-8.0%
Return on Equity (ROE)
-8.4%
Dividend Yield
-
Payout Ratio
-
Financial Health
Total Assets
22.6M
Total Debt
1.0M
Debt to Equity
0.05x
Current Ratio
0.19
Company Info
| Industry | Biotechnology |
| HQ | Edmonton, Canada |
| Fiscal Year End | 1738281600 |
| Currency | CAD |
| Website | www.questpharmatech.com |
Peers
Bausch + Lomb Corporation
BLCO.TO
7.9B
P/E: --
Bausch Health Companies Inc.
BHC.TO
2.5B
P/E: 12.0
Extendicare Inc.
EXE.TO
2.5B
P/E: 23.7
Sienna Senior Living Inc.
SIA.TO
2.2B
P/E: 53.2
Cronos Group Inc.
CRON.TO
1.4B
P/E: 24.1
Tilray Brands, Inc.
TLRY.TO
1.2B
P/E: --
WELL Health Technologies Corp.
WELL.TO
1.1B
P/E: --
Knight Therapeutics Inc.
GUD.TO
631.8M
P/E: --
Insider Activity
Sentiment
Bullish
Shares Bought
2,000,000
Shares Sold
0
Total Transactions
3
SEDAR+ Filings
View All Filings8
Annual Reports
28
Quarterly Reports
37
MD&A
39
News Releases
3
Material Changes
12
Governance
76
Certifications
47
Other
●
2020-04-28
●
2020-04-28
●
2018-12-07
Interactive Charts
Company Profile
General Information
| Company Name | Quest PharmaTech Inc. |
| Ticker | QPT.V |
| Exchange | TSXV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Headquarters | Edmonton, Canada |
| Fiscal Year End | 1738281600 |
| Currency | CAD |
| Website | www.questpharmatech.com |
Financial Summary
| Market Cap | 5.1M |
| Revenue | N/A |
| Net Income | -1.8M |
| P/E Ratio | N/A |
| EPS (Diluted) | C$-0.01 |
| Net Margin | N/A |
| ROE | -8.4% |
| Dividend Yield | N/A |
Business Description
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. The company's lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16 for the potential cancer targets, including pancreatic, colon, leukemia, ovarian, and breast cancer. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.